J Narváez

Socio-demographic predictors of age at menarche in a group of Colombian university women

Background: Age at menarche is an important developmental milestone known to be modified by social and environmental factors. The determinants and potential change over time of age at menarche in Colombia are not well documented. Aims: To obtain a current estimate of age at menarche in Colombia and to examine the associations between socio-demographic characteristics and age at menarche. Subjects and methods: Between 1998 and 2001, we obtained recalled age at menarche, socio-demographic characteristics, and physical activity information in a group of 3206 students at the National University of Colombia who completed a self-administered questionnaire. We examined the cross-sectional associations between mean age at menarche and migratory pattern, parental education, socio-economic status indicators, practice of physical activity, and year of birth using linear regression. Results: Mean age at menarche (± SD) was 12.68 ± 1.31. In a multivariate adjusted regression model, age at menarche was positively associated with family size and the practice of at least 2 daily hours of physical activity, and was inversely related to urbanization level, socio-economic status, and year of birth. Conclusions: Socio-economic status is a strong predictor of menarche in this population. There appears to be a trend towards earlier menarche by year of birth.

Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.

A complete economic study was carried out to assess the economical impact of two rotavirus vaccine in Colombia. A Markov decision model was built to assess the health outcomes from birth to 24 months of age for three hypothetical cohorts: one unvaccinated, one vaccinated with 2 doses of Rotarix and the third, with 3 doses of Rotateq. Without vaccination, the annual number of medical visits by diarrhea in children under 2 years would be 1,293,159 cases, with 105,378 medical visits and 470 deaths (IC95% 295-560) related to rotavirus. Without vaccination, rotavirus disease would cost around USD

Impacto económico de la introducción de la vacuna inactivada inyectable contra la poliomielitis en Colombia

8 millions including direct and indirect costs. Assuming a cost per dose of USD

Evaluación de la Carga de Enfermedad por el Virus del Papiloma Humano en Bogotá

7.5, average cost-effectiveness ratio would be USD

Is Colombia reaching the goals on infant immunization coverage? A quantitative survey from 80 municipalities

663/DALY with Rotarix and USD

Combination of five diagnostic tests to estimate the prevalence of hookworm infection among school-aged children from a rural area of colombia

1391 with Rotateq. When price per dose falls below USD

Theoretical estimation of the epidemiological impact of hepatitis A infection in Colombia

7 both vaccines yield a similar average cost-effectiveness ratio (USD

Time to first pregnancy among women working in agricultural production.

1063/DALY). Incremental cost-effectiveness ratio of Rotateq versus Rotarix was USD

PRS16 AN ECONOMIC EVALUATION OF A PHARMACOLOGICAL INTERVENTION USING VARENICLINE AS THERAPY FOR SMOKING CESSATION

7787/DALY. Cost-effectiveness ratio was influenced mainly by vaccine cost and cost per case hospitalized. Other programmatic aspects such as number of doses to be applied, likelihood of completing vaccination schedule with shorter versus longer schedules, and storage space within the chain cold should be considered to make decisions on which vaccine should be introduced. In conclusion, vaccinating against rotavirus in Colombia with either vaccine would be very cost effective. If cost per vaccinated children falls below USD

Vaccination coverage in colombia, opportunity and factors associated: Results from a national survey

3 per dose vaccination would be cost saving.